Key facts
- This page summarizes Carl Ashley Morris's Form 4 filing for Solid Biosciences Inc. (SLDB).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 31 Jan 2023, 20:18.
Carl Ashley Morris - 27 Jan 2023 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- SLDB
- Reported as of
- 27 Jan 2023
- Net transaction value
- -$3,303
- SEC form
- 4
- Accepted by SEC
- 31 Jan 2023, 20:18:53 UTC
- Prior SEC filing
- 05 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ by David Tyrone Howton as attorney-in-fact for Carl Ashley Morris
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Carl Ashley Morris filed Form 4 for Solid Biosciences Inc. (SLDB) on 31 Jan 2023.
Change
- Previous filing in this sequence was filed on 05 Jan 2023.
- Current net transaction value: -$3,303.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SLDB
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,233
- Change %
- +6.5%
- Price
- Shares after
- 20,201
- Date
- 27 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2
SLDB
transaction
Common Stock
Sale
- Transaction value
- $3,303
- Shares
- -441
- Change %
- -2.2%
- Price
- $7.49
- Shares after
- 19,760
- Date
- 27 Jan 2023
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SLDB
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,233
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 3,700
- Date
- 27 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,233
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
Includes 490 shares of common stock and 1,462 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2022 and November 30, 2022, respectively.
Footnote F3
This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).
Footnote F4
On January 27, 2022 (the "Grant Date"), the reporting person was granted 4,933 restricted stock units, vesting in four equal installments on the anniversary of the grant date.